Summit Therapeutics Inc. SMMT
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Each USD of equity lost 206 cents this year.
The 7-year record
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenue $B | ◌ | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 |
| Operating income $B | −1.1 | −0.2 | −0.6 | −0.1 | −0.1 | −0.1 | 0.0 |
| EBITDA $B | −1.1 | −0.2 | −0.6 | −0.1 | −0.1 | −0.1 | 0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | ◌ | 0.0 | −0.0 | −0.0 |
| Net income $B | −1.1 | −0.2 | −0.6 | −0.1 | −0.1 | −0.1 | 0.0 |
| Free cash flow $B | −0.3 | −0.1 | −0.1 | −0.0 | −0.1 | −0.0 | −0.0 |
| EPS, diluted $ | −1.44 | −0.31 | −0.99 | −0.41 | −0.67 | −0.76 | 0.63 |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % | — | — | — | — | — | −0 | 0 |
| ROE % | −206.1 | −94.9 | −601.8 | −75.1 | −108.9 | −66.3 | 18.9 |
| Shares out B | 0.78 | 0.74 | 0.70 | 0.21 | 0.10 | 0.08 | ◌ |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Company facts, as filed
Reconciled in 7 of the 7 fiscal years we could check. 26 checks were skipped: the balance sheet is not tagged before 2020. 11 checks were skipped: EPS is not tagged before 2018.